Apogee Therapeutics

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

Apogee has secured a promise of up to $1.3 billion from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.

James Waldron May 27, 2026 8:57am

target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am

eczema atopic dermatitis Black African American patient skin of color

Apogee claims IL-13 antibody sets new eczema treatment standard

Jul 7, 2025 8:29am

Sanofi finds new R&D head—Chutes & Ladders

Sep 1, 2023 9:30am

Wall Street stock exchange finance shares share price Nasdaq

Apogee, Sagimet overshoot IPO expectations as they reach Nasdaq

Jul 14, 2023 8:55am

2 biotechs test icy IPO waters with $228M and $66M offerings

Jul 10, 2023 11:43am